- Sylentis has reached the target of recruiting patients for its Phase III trial "HELIX" for the treatment of the signs and symptoms of dry eye disease
- PharmaMar estimate that the results of the trial will be available in the first four months of 2019
PR Newswire
MADRID, Oct. 19, 2018